Advanced Biomed Inc. Common Stock
Advanced Biomed Inc. Common Stock Fundamental Analysis
Advanced Biomed Inc. Common Stock (ADVB) shows moderate financial fundamentals with a PE ratio of 11.02, profit margin of 0.00%, and ROE of 94.69%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 62.1/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze ADVB's fundamental strength across five key dimensions:
Efficiency Score
ExcellentADVB demonstrates superior asset utilization.
Valuation Score
ExcellentADVB trades at attractive valuation levels.
Growth Score
ModerateADVB shows steady but slowing expansion.
Financial Health Score
ExcellentADVB maintains a strong and stable balance sheet.
Profitability Score
WeakADVB struggles to sustain strong margins.
Key Financial Metrics
Is ADVB Expensive or Cheap?
P/E Ratio
ADVB trades at 11.02 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, ADVB's PEG of 0.05 indicates potential undervaluation.
Price to Book
The market values Advanced Biomed Inc. Common Stock at 7.13 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -5.36 times EBITDA. This is generally considered low.
How Well Does ADVB Make Money?
Net Profit Margin
For every $100 in sales, Advanced Biomed Inc. Common Stock keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $94.69 in profit for every $100 of shareholder equity.
ROA
Advanced Biomed Inc. Common Stock generates $55.98 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $-0.24 in free cash annually.
FCF Yield
ADVB converts -70.01% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
11.02
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.05
vs 25 benchmark
P/B Ratio
Price to book value ratio
7.13
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
7.38
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.95
vs 25 benchmark
ROA
Return on assets percentage
0.56
vs 25 benchmark
ROCE
Return on capital employed
-0.16
vs 25 benchmark
How ADVB Stacks Against Its Sector Peers
| Metric | ADVB Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 11.02 | 28.62 | Better (Cheaper) |
| ROE | 94.69% | 783.00% | Weak |
| Net Margin | 0.00% | -48181.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.39 | Strong (Low Leverage) |
| Current Ratio | 7.38 | 4.12 | Strong Liquidity |
| ROA | 55.98% | -21914.00% (disorted) | Strong |
ADVB outperforms its industry in 4 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Advanced Biomed Inc. Common Stock's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation